Compare PGNY & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGNY | AVDL |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2019 | 1996 |
| Metric | PGNY | AVDL |
|---|---|---|
| Price | $26.24 | $21.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $27.44 | $18.38 |
| AVG Volume (30 Days) | 1.5M | ★ 2.8M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.96 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $1,268,689,000.00 | $248,517,000.00 |
| Revenue This Year | $11.55 | $65.47 |
| Revenue Next Year | $9.52 | $30.88 |
| P/E Ratio | $43.27 | ★ N/A |
| Revenue Growth | 11.41 | ★ 79.88 |
| 52 Week Low | $13.86 | $6.38 |
| 52 Week High | $27.51 | $23.57 |
| Indicator | PGNY | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 63.07 | 59.42 |
| Support Level | $23.78 | $21.34 |
| Resistance Level | $25.27 | $21.55 |
| Average True Range (ATR) | 0.86 | 0.24 |
| MACD | -0.05 | -0.24 |
| Stochastic Oscillator | 69.55 | 13.46 |
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.